New HPV vaccine combo shows promise in fighting Hard-to-Treat cancers
NCT ID NCT04432597
First seen Dec 10, 2025 · Last updated Jun 13, 2026 · Updated 28 times
Summary
This study tests an HPV vaccine (PRGN-2009) alone or combined with a drug called M7824 in people with HPV-positive cancers that have spread or come back. The goal is to find a safe dose and see if the combination boosts the immune system to fight the cancer better. Participants receive the vaccine as a shot and M7824 as an infusion, with treatment lasting up to a year.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CERVICAL CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
National Institutes of Health Clinical Center
Bethesda, Maryland, 20892, United States
Conditions
Explore the condition pages connected to this study.